共 50 条
- [1] EFFICACY AND SAFETY OF OLOKIZUMAB IN A PHASE III TRIAL OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RA INADEQUATELY CONTROLLED BY METHOTREXATE: PLACEBO AND ACTIVE CONTROLLED STUDY[J]. RHEUMATOLOGY, 2021, 60Feist, EugenChohan, SaimaFatenejad, SaeedGrishin, SergeyKorneva, ElenaNasonov, Evgeniy L.Rowinska-Osuch, AnnaSamsonov, Mikhail
- [2] Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate-CREDO1 Study[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71Nasonov, EvgeniyFatenejad, SaeedKorneva, ElenaKrechikova, DianaMaslyansky, AlexeyPlaksina, TatyanaStanislav, MarinaStoilov, RumenTyabut, TamaraYakushin, SergeyZonova, ElenaGenovese, Mark
- [3] P131 Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study[J]. RHEUMATOLOGY, 2021, 60Feist, EugenChohan, SaimaFatenejad, SaeedGrishin, SergeyKorneva, ElenaNasonov, Evgeniy L.Rowinska-Osuch, AnnaSamsonov, Mikhail
- [4] Efficacy and Safety of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by TNF-α Inhibitor Therapy[J]. ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3510 - 3513Feist, EugenFatenejad, SaeedGrishin, SergeyKorneva, ElenaLuggen, MichaelNasonov, EvgeniySamsonov, MikhailFleischmann, Roy
- [5] EFFICACY AND SAFETY OF OLOKIZUMAB IN A PHASE III TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RA INADEQUATELY CONTROLLED BY TNF-a INHIBITOR THERAPY[J]. RHEUMATOLOGY, 2021, 60 : 75 - 75Feist, EugenFatenejad, SaeedGrishin, SergeyKorneva, ElenaLuggen, MichaelNasonov, EvgeniySamsonov, Mikhail
- [6] OLOKIZUMAB, MONOCLONAL ANTIBODY AGAINST IL6, IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: EFFICACY AND SAFETY RESULTS OF PHASE III CREDO-1 STUDY[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 16 - 17Nasonov, E.Stoilov, R.Tyabut, T.Genoveseon, M. C.Krechikova, DianaKorneva, ElenaMaslyansky, AlexeyPlaksina, TatianaStanislav, MarinaYakushin, SergeyZonova, Elena
- [7] Olokizumab Improves Patient Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate: Results from the Double-Blind, Randomized Controlled Phase III Study[J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72Nasonov, EvgenyFatenejad, SaeedIvanova, MarianaKrechikova, DianaKuzkina, SofiaMaslyanskiy, AlexeyPlaksina, TatianaSamsonov, MikhailStanislav, MarinaTyabut, TamaraVinogradova, IrinaYakushin, SergeyZonova, ElenaGenovese, Mark
- [8] P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-alpha inhibitor therapy[J]. RHEUMATOLOGY, 2021, 60Feist, EugenFatenejad, SaeedGrishin, SergeyKorneva, ElenaLuggen, MichaelNasonov, EvgeniySamsonov, Mikhail
- [9] Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial[J]. ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 611 - 612Strand, VibekeNasonov, EvgenyLisitsyna, TatianaLila, AlexanderKuzkina, SofiaSamsonov, MikhailFeist, Eugen
- [10] OLOKIZUMAB IMPROVES PATIENT REPORTED OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS INADEQUATELY CONTROLLED BY METHOTREXATE: RESULTS FROM THE DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE III STUDY (CREDO-1)[J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 300 - 301Nasonov, E.Ivanova, M.Samsonov, M.Tyabut, T.Genovese, M. C.Fatenejad, SaeedKrechikova, DianaKuzkina, SofiaMaslyansky, AlexeyPlaksina, TatianaStanislav, MarinaYakushin, SergeyZonova, Elena